Jump Financial LLC Has $1.36 Million Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Jump Financial LLC raised its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 279.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 141,938 shares of the biopharmaceutical company's stock after purchasing an additional 104,518 shares during the quarter. Jump Financial LLC owned about 0.26% of Emergent BioSolutions worth $1,357,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Covestor Ltd boosted its stake in Emergent BioSolutions by 5,458.5% during the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 2,893 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in Emergent BioSolutions in the 4th quarter valued at about $63,000. E Fund Management Co. Ltd. bought a new position in shares of Emergent BioSolutions during the 4th quarter valued at about $98,000. Stifel Financial Corp acquired a new position in shares of Emergent BioSolutions in the 3rd quarter worth approximately $96,000. Finally, Cornercap Investment Counsel Inc. bought a new stake in shares of Emergent BioSolutions in the 4th quarter worth approximately $115,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Trading Up 5.6 %

Shares of EBS stock traded up $0.27 during trading hours on Wednesday, reaching $4.99. 1,090,673 shares of the stock traded hands, compared to its average volume of 2,645,490. The business has a fifty day moving average price of $5.78 and a 200 day moving average price of $8.25. Emergent BioSolutions Inc. has a 1-year low of $1.82 and a 1-year high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The firm has a market capitalization of $270.87 million, a PE ratio of -1.22 and a beta of 2.14.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.40. The company had revenue of $194.70 million during the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter last year, the business posted ($0.77) EPS. On average, equities research analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Emergent BioSolutions announced that its board has authorized a stock repurchase plan on Monday, March 31st that allows the company to repurchase $50.00 million in shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 19% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's management believes its shares are undervalued.

Insider Activity at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now directly owns 101,100 shares in the company, valued at approximately $589,413. This trade represents a 25.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. StockNews.com cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Emergent BioSolutions in a report on Tuesday, April 1st.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.